BeStock  
Stocks › IOVA

Iovance Biotherapeutics IOVA

US equityMarket cap rank #2386
$6.90 −$0.41 (-5.61%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $6.99 +1.25%
Open$7.17
Prev close$7.31
Day range$6.77 – $7.40
Volume13.73M
Market cap$3.19B
P/E (TTM)–
Dividend yield–

IOVA Stock News

Headlines matching Iovance Biotherapeutics or the IOVA ticker, most recent first.

  • A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $15 to $20Market news · 30 Sep 2026 · Direct mention
  • Goldman Sachs Upgrades Iovance Biotherapeutics(IOVA.US) to Buy Rating, Raises Target Price to $15 PositiveMarket news · 24 Sep 2026 · Direct mention
  • Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $15 PositiveMarket news · 17 Sep 2026 · Direct mention
  • Citizens JMP Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $8 PositiveMarket news · 8 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $7 to $13Market news · 7 Aug 2026 · Direct mention
  • TD Cowen Initiates Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $10Market news · 25 Aug 2026 · Direct mention
  • Mizuho Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $11 PositiveMarket news · 18 Aug 2026 · Direct mention
  • Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $11Market news · 20 Jul 2026 · Direct mention
  • H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $9Market news · 4 Jun 2026 · Direct mention
  • A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $5 to $14Market news · 8 May 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Actuate Therapeutics, Inc. (ACTU), Iovance Biotherapeutics (IOVA) and Otsuka Holdings Co (OtherOTSKF)TipRanks · 22 Apr 2026 · Direct mention
  • Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $16Market news · 11 Apr 2026 · Direct mention
  • Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Sell Rating, Raises Target Price to $2 PositiveMarket news · 5 Feb 2026 · Direct mention
  • Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $10Market news · 4 Feb 2026 · Direct mention
  • Wells Fargo Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $14Market news · 26 Feb 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on IOVA.

Sign in to join the discussion.

Scroll to Top